ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,461 to 1,480 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Expectant Management vs Elective Induction of Labor: deaths from any cause3 of 3,059

2 of 3,037

0.0 points

-0.2 to 0.2

6,096NCT01990612

A Randomized Trial of Induction Versus Expectant Management

Expectant Management vs Elective Induction of Labor: Number of Participants Who Had Uterine Incisional Extension at Cesarean Delivery48 of 3,037

28 of 3,059

0.7 points

0.1 to 1.2

6,096NCT01990612

A Randomized Trial of Induction Versus Expectant Management

Expectant Management vs Elective Induction of Labor: serious adverse events3 of 3,037

2 of 3,059

0.0 points

-0.2 to 0.2

6,096NCT01990612

A Randomized Trial of Induction Versus Expectant Management

Expectant Management vs Elective Induction of Labor: Number of Infants With Hyperbilirubinemia142 of 3,034

145 of 3,058

-0.1 points

-1.1 to 1.0

6,092NCT01990612

A Randomized Trial of Induction Versus Expectant Management

Fluarix Tetra vs mRNA-1010: Number of Participants With Unsolicited AEs749 of 3,048

800 of 3,035

-1.8 points

-4.0 to 0.4

6,083NCT05415462

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Fluarix Quadrivalent 60 ug vs mRNA-1010 50 ug: serious adverse events131 of 3,048

132 of 3,035

-0.1 points

-1.1 to 1.0

6,083NCT05415462

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Lixisenatide vs Placebo: Time to First Occurence of Primary CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke or Hospitalization for Unstable Angina406 of 3,034

399 of 3,034

0.2 points

-1.5 to 1.9

6,068NCT01147250

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Lixisenatide vs Placebo: Time to First Occurence of CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke, Hospitalization for Unstable Angina or Hospitalization For Heart Failure456 of 3,034

469 of 3,034

-0.4 points

-2.2 to 1.4

6,068NCT01147250

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Lixisenatide vs Placebo: Time to First Occurence of CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke, Hospitalization for Unstable Angina, Hospitalization For Heart Failure or Coronary Revascularization Procedure661 of 3,034

659 of 3,034

0.1 points

-2.0 to 2.1

6,068NCT01147250

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Pre-Intervention vs Post-Intervention: Individuals With an Intravenous Line2,004 of 3,243

2,056 of 2,823

-11.0 points

-13.4 to -8.7

6,066NCT00234286

Intervention to Improve Care at Life's End

Pre-Intervention vs Post-Intervention: Individuals With a Nasogastric Tube1,293 of 3,243

922 of 2,823

7.2 points

4.8 to 9.6

6,066NCT00234286

Intervention to Improve Care at Life's End

Pre-Intervention vs Post-Intervention: Individuals With an Order for Benzodiazepine Medication1,102 of 3,243

1,185 of 2,823

-8.0 points

-10.4 to -5.5

6,066NCT00234286

Intervention to Improve Care at Life's End

Pre-Intervention vs Post-Intervention: Individuals Who Received Benzodiazepine Medication710 of 3,243

675 of 2,823

-2.0 points

-4.1 to 0.1

6,066NCT00234286

Intervention to Improve Care at Life's End

Pre-Intervention vs Post-Intervention: Individuals With an Order for Antipsychotic Medication336 of 3,243

661 of 2,823

-13.1 points

-14.9 to -11.2

6,066NCT00234286

Intervention to Improve Care at Life's End

Pre-Intervention vs Post-Intervention: Individuals With an Advance Directive1,194 of 3,243

1,306 of 2,823

-9.4 points

-11.9 to -7.0

6,066NCT00234286

Intervention to Improve Care at Life's End

Pre-Intervention vs Post-Intervention: Number of Individuals Who Died in Restraints531 of 3,243

362 of 2,823

3.6 points

1.8 to 5.3

6,066NCT00234286

Intervention to Improve Care at Life's End

Pre-Intervention vs Post-Intervention: Individuals With a Palliative Care Consultation184 of 3,243

885 of 2,823

-25.7 points

-27.6 to -23.8

6,066NCT00234286

Intervention to Improve Care at Life's End

Pre-Intervention vs Post-intervention: Individuals Administered of Opioid Medication1,569 of 3,243

1,662 of 2,823

-10.5 points

-13.0 to -8.0

6,066NCT00234286

Intervention to Improve Care at Life's End

Pre-Intervention vs Post-Intervention: Individuals Who Received Scopolamine113 of 3,243

633 of 2,823

-18.9 points

-20.6 to -17.3

6,066NCT00234286

Intervention to Improve Care at Life's End

Pre-Intervention vs Post-Intervention: Number of Patients Who Died in ICU1,312 of 3,243

1,046 of 2,823

3.4 points

0.9 to 5.9

6,066NCT00234286

Intervention to Improve Care at Life's End

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=74

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01990612-deaths",
        "title": "Expectant Management vs Elective Induction of Labor: deaths from any cause",
        "summary": "3 of 3059 against 2 of 3037; risk difference 0.0 points, 95% interval -0.2 to 0.2; NCT01990612, A Randomized Trial of Induction Versus Expectant Management",
        "record": "/library/comparisons/NCT01990612-deaths",
        "nct_id": "NCT01990612",
        "kind": "deaths",
        "participants": 6096,
        "risk_difference": {
          "value": 0.0003221680347954395,
          "lower": -0.001533854617283841,
          "upper": 0.0022802706230753323
        },
        "group_1": "3 of 3,059",
        "group_2": "2 of 3,037",
        "difference": "0.0 points",
        "interval": "-0.2 to 0.2",
        "trial_title": "A Randomized Trial of Induction Versus Expectant Management"
      },
      {
        "id": "NCT01990612-ebb09a66",
        "title": "Expectant Management vs Elective Induction of Labor: Number of Participants Who Had Uterine Incisional Extension at Cesarean Delivery",
        "summary": "48 of 3037 against 28 of 3059; risk difference 0.7 points, 95% interval 0.1 to 1.2; NCT01990612, A Randomized Trial of Induction Versus Expectant Management",
        "record": "/library/comparisons/NCT01990612-ebb09a66",
        "nct_id": "NCT01990612",
        "kind": "outcome",
        "participants": 6096,
        "risk_difference": {
          "value": 0.006651752715743061,
          "lower": 0.0010589838109953164,
          "upper": 0.012464271301226883
        },
        "group_1": "48 of 3,037",
        "group_2": "28 of 3,059",
        "difference": "0.7 points",
        "interval": "0.1 to 1.2",
        "trial_title": "A Randomized Trial of Induction Versus Expectant Management"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=75",
  "request_id": "jLUNAAlmAnVZyrgO"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?